Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression

Molecular Cancer Therapeutics

Volumn 14, Issue 10, 2015, Pages 2167-2174

  Lenhart, Ryan ^a   Kirov, Stefan ^a   Desilva, Heshani ^a   Cao, Jian ^a   Lei, Ming ^a   Johnston, Kathy ^a   Peterson, Russell ^a   Schweizer, Liang ^a   Purandare, Ashok ^a   Ross Macdonald, Petra ^a   Fairchild, Craig ^a   Wong, Tai ^a,b   Wee, Susan ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Peloton Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; BET PROTEIN; BRD4 PROTEIN; MYC PROTEIN; MYCN PROTEIN; PROTEIN; TRANSCRIPTION FACTOR MASH1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; (+)-JQ1 COMPOUND; ANTINEOPLASTIC AGENT; ASCL1 PROTEIN, HUMAN; AZEPINE DERIVATIVE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BRD4 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENHANCER REGION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC50; NEUROENDOCRINE TUMOR; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA INTERFERENCE; SMALL CELL LUNG CANCER; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; AZEPINES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENHANCER ELEMENTS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; NUCLEAR PROTEINS; PROTEIN BINDING; SMALL CELL LUNG CARCINOMA; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TRIAZOLES;

EID: 84946761781     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0037     Document Type: Article

References (34)

1. Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett 2002;1:124-8.
2. Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R. The bromodomain revisited. Trends Biochem Sci 1997;22:151-3.
3. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation, and cancer. Nat Rev Cancer 2012;12:465-77.
4. Filippakopoulos P, Qi J, Picaud J, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET domains. Nature 2010;468:1067-73.
5. Mirguet O, Gosmini R, Toum J. Discovery of epigenetic regulator i-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem 2013;56:7501-15.
6. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-myc. Cell 2011;146:904-17.
7. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108:16669-74.
8. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524-30.
9. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan W, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478:529-33.
10. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, et al. Superenhancers in the control of identify and disease. Cell 2013;155:934-47.
11. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320-34.
12. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A 2012;109:19408-13.
13. Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res 2013;19:1748-59.
14. Shimamura T, Chen Z, Soucheray M, Carretero J, Kekuchi E, Tchaicha JH, et al. Efficacy of BET bromodomain inhibition in KRas-mutant non-small cell lung cancer. Clin Cancer Res 2013;19:6183-92.
15. Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, et al. Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget 2013;4:2419-29.
16. Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997;386:852-5.
17. Jiang T, Collins BJ, Jin N, Watkins DN, Brock MV, Matsui W, et al. Achaetescute complex homologue 1 regulates tumor-initiating capacity in human small-cell lung cancer. Cancer Res 2009;69:845-54.
18. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A 2014;111:14788-93.
19. Ji RR, de Silva H, Jin Y, Bruccoleri RE, Cao J, He A, et al. Transcription profiling of the dose response: amore powerful approach for characterizing drug activities. PLoS Comput Biol 2009;5:e1000512.
20. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucl Acid Res 2003;31:e15.
21. Chin GM, Herbst R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 2006;10:2580-91.
22. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74.
23. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805-11.
24. Yik JHN, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of p-TEFb (cdk9/cyclin T) kinase and RNA polymerase II transcription by the coordinate actions of HEXIM1 and 7SK snRNA. Mol Cell 2003;12:971-82.
25. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 2012;287:36609-16.
26. Ding KK, Shang ZF, Hao C, Xu QZ, Shen JJ, Yan CJ, et al. Induced expression of the IER5 gene by γ-irradiation and its involvement in cell cycle checkpoint control and survival. Radiat Environ Biophys 2009;48: 205-13.
27. Inbal B, Shani G, Cohen O, Kissil J, Kimchi A. Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol Cell Biol 2000;20:1044-54.
28. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-8.
29. Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer Res 1992;52:2732S-6S.
30. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-12.
31. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell-cycle progression. Mol Cell Biol 2008;28:967-76.
32. Osada H, Tatematsu Y, Yatabe Y, Horio Y, Takahashi T. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005;65:10680-5.
33. Castro DS, Martynoga B, Parras C, Ramesh V, Pacary E, Johnston C, et al. A novel function of the proneural factor Ascl1 in progenitor proliferation identitifed by genome-wide characterization of its targets. Genes Dev 2011;25:930-45.
34. Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, et al. Targeting transcriptional addiction in small-cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 2014;26:909-22.